Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
ConclusionsApixaban, compared with warfarin, was associated with fewer intracranial hemorrhages, less adverse consequences following extracranial hemorrhage, and a 50% reduction in fatal consequences at 30 days in cases of major hemorrhage.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - Category: Cardiology Source Type: research
More News: Aspirin | Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Coumadin | Diabetes | Endocrinology | Heart | Hemorrhagic Stroke | Ischemic Stroke | Stroke | Study | Thrombosis | Warfarin